<DOC>
	<DOCNO>NCT01251341</DOCNO>
	<brief_summary>The increasingly widespread use meditation stress-related emotional medical condition highlight urgent need rigorously evaluate mechanism benefit practice might confer . Primary challenge regard include evaluate dose response relationship practice time outcomes ; clarify whether physiological behavioral effect meditation derive primarily non-specific aspect train result specific meditation practice ; identify molecular mechanism meditation might affect physiological response relevant stress-related illness . Recent finding cross-sectional study group indicate young adult randomize , practice , compassion meditation demonstrate reduce inflammatory response , less emotional distress , reduce autonomic response standardize laboratory psychosocial stressor ( Trier Social Stress Test [ TSST ] ) compare subject randomize active control condition . However , result cross-sectional study design lack meditation comparator arm , result provide partial insight key issue outline regard role play specific meditation procedure and/or practice time observe physiological behavioral outcome . The primary hypothesis propose work practice meditation procedure specifically design enhance empathic concern others ( i.e . compassion meditation ) optimize autonomic reactivity psychosocial stress manner result diminish activation peripheral inflammatory signal pathway reduce behavioral distress .</brief_summary>
	<brief_title>The Compassion Attention Longitudinal Meditation Study</brief_title>
	<detailed_description />
	<criteria>Good medical health current major depression current substance abuse lifetime history schizophrenia bipolar disorder type I assess Structured Diagnostic Interview DSMIV ( SCID ) suicidal ideation suicide attempt within one year study enrollment diagnosis serious ongoing medical condition include malignancy , autoimmune disease ( i.e . rheumatoid arthritis , multiple sclerosis , Crohn 's disease ) , cardiovascular disease ( hypertension ) , seizure disorder , endocrinopathy , chronic infection ( i.e . human immunodeficiency virus , hepatitis B C ) , renal hepatic insufficiency , current past medical psychiatric condition might increase risk study participation opinion study personnel treatment psychotropic medication within last year ( i.e . antidepressant , anxiolytic , psychostimulants mood stabilizer ) active ongoing psychiatric treatment time enrollment . use psychotropic medication ( i.e . antidepressant , anxiolytic , psychostimulants mood stabilizer ) within one year screening . chronic use antiinflammatory/immunosuppressive agent , include , limited , aspirin , nonsteroidal antiinflammatory agent , COX2 inhibitor , corticosteroid , etanercept , infliximab , adalimumab methotrexate . significant past meditation training/experience ( define meditate 3 time week period longer month )</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>inflammation</keyword>
	<keyword>immune system</keyword>
	<keyword>cytokine</keyword>
	<keyword>meditation</keyword>
	<keyword>compassion</keyword>
	<keyword>attention</keyword>
</DOC>